Phenotypes associated with this allele

• Allele Symbol: Fas^tm1Cgn
• Allele Name: targeted mutation 1, University of Cologne
• Allele ID: MGI:3690464
• Summary: 12 genotypes

Jump to	Allelic Composition	Genetic Background	Genotype ID
hm1	Fas^tm1Cgn/Fas^tm1Cgn	C57BL/6-Fas^tm1Cgn	MGI:3690545
cn2	Cd19^tm1(cre)Cgn/Cd19^+ Fas^tm1Cgn/Fas^tm1Cgn	B6.Cg-Cd19^tm1(cre)Cgn Fas^tm1Cgn	MGI:3690548
cn3	Fas^tm1Cgn/Fas^tm1Cgn Cd19^tm1(cre)Cgn/Cd19^+ Tg(Cd4-cre)1Cwi/0	B6.Cg-Tg(Cd4-cre)1Cwi Cd19^tm1(cre)Cgn Fas^tm1Cgn	MGI:3690549
cn4	Fas^tm1Cgn/Fas^tm1Cgn Tg(Cd4-cre)1Cwi/0	B6.Cg-Tg(Cd4-cre)1Cwi Fas^tm1Cgn	MGI:3690546
cn5	Fas^tm1Cgn/Fas^tm1Cgn Tg(Lck-cre)I57Jxm/0	B6.Cg-Fas^tm1Cgn Tg(Lck-cre)I57Jxm	MGI:3690547
cn6	Fas^tm1Cgn/Fas^tm1Cgn Tg(Mx1-cre)1Cgn/0	B6.Cg-Fas^tm1Cgn Tg(Mx1-cre)1Cgn	MGI:3690550
cn7	Cd19^tm1(cre)Cgn/Cd19^+ Fas^lpr/Fas^tm1Cgn Tg(Cd4-cre)1Cwi/0	involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL	MGI:3690553
cn8	Cd19^tm1(cre)Cgn/Cd19^+ Fas^lpr/Fas^tm1Cgn	involves: 129P2/OlaHsd * C57BL/6 * MRL	MGI:3690552
cn9	Fas^tm1Cgn/Fas^tm1Cgn Mog^tm1(cre)Gkl/Mog^+ Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak	involves: 129S2/SvPas * C57BL/6	MGI:3690542
cn10	Fas^tm1Cgn/Fas^tm1Cgn Mog^tm1(cre)Gkl/Mog^+	involves: C57BL/6	MGI:3690541
cn11	Fas^lpr/Fas^tm1Cgn Tg(Cd4-cre)1Cwi/0	involves: C57BL/6 * DBA/2 * MRL	MGI:3690551
cx12	Fas^tm1Cgn/Fas^tm1Cgn Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak	involves: 129S2/SvPas * C57BL/6	MGI:3690543

Genotype
MGI:3690545

hm1

• Allelic Composition: Fas^tm1Cgn/Fas^tm1Cgn
• Genetic Background: C57BL/6-Fas^tm1Cgn

• ♀: phenotype observed in females
• ♂: phenotype observed in males
• N: normal phenotype

immune system

immune system phenotype ( J:114948 )

N • normal lymphocyte development and subset distribution

Genotype
MGI:3690548

cn2

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Fas^tm1Cgn/Fas^tm1Cgn
• Genetic Background: B6.Cg-Cd19^tm1(cre)Cgn Fas^tm1Cgn

immune system

increased anti-single stranded DNA antibody level ( J:114948 )

• 3- to 8-fold increase in IgM and IgG antibodies for single stranded DNA; however, this is 2- to 3-fold lower than in mice homozygous for Fas^tm1.1Cgn and mice do not display the increase in double negative T cells or lymphoproliferative disease seen in Fas^lpr homozygotes

Genotype
MGI:3690549

cn3

• Allelic Composition: Fas^tm1Cgn/Fas^tm1Cgn; Cd19^tm1(cre)Cgn/Cd19⁺; Tg(Cd4-cre)1Cwi/0
• Genetic Background: B6.Cg-Tg(Cd4-cre)1Cwi Cd19^tm1(cre)Cgn Fas^tm1Cgn

immune system

increased anti-single stranded DNA antibody level ( J:114948 )

• 3- to 8-fold increase in IgM and IgG antibodies for single stranded DNA; however, this is 2- to 3-fold lower than in mice homozygous for Fas^tm1.1Cgn and mice do not display the increase in double negative T cells or lymphoproliferative disease seen in Fas^lpr homozygotes

Genotype
MGI:3690546

cn4

• Allelic Composition: Fas^tm1Cgn/Fas^tm1Cgn; Tg(Cd4-cre)1Cwi/0
• Genetic Background: B6.Cg-Tg(Cd4-cre)1Cwi Fas^tm1Cgn

mortality/aging

premature death ( J:114948 )

• 75% of mice die between 10 and 18 months of age

immune system

increased T cell apoptosis ( J:114948 )

• loss of B and T cells is at least in part the result of increased apoptosis

abnormal thymus involution ( J:114948 )

• thymus cell numbers decline from normal at 2 months of age to about 50% and 10% of control at 5 and 7 months of age, respectively

• occasionally complete thymic involution is seen at 7 months of age

abnormal immune system cell morphology ( J:114948 )

increased double-negative T cell number ( J:114948 )

• treatment with a neutralizing Fasl antibody results in accumulation of Thy1+ B220+ CD4- CD8- cells similar to the phenotype of Fas^lpr homozygous mice

decreased B cell number ( J:114948 )

• gradual decline in B cell numbers in secondary lymphoid organs beginning after 2 months of age resulting in almost complete lymphopenia in the lymph nodes

• treatment with a neutralizing Fasl antibody prevents loss of B cells from the inguinal lymph nodes

increased memory T cell number ( J:114948 )

• the fraction of activated/memory T cells in the spleen increases from nearly normal at 2 months of age to about 91% at 7 months of age

decreased T cell number ( J:114948 )

• gradual decline in T cell numbers in secondary lymphoid organs beginning after 2 months of age resulting in almost complete lymphopenia in the lymph nodes

• treatment with a neutralizing Fasl antibody prevents loss of T cells from the inguinal lymph nodes

increased activated T cell number ( J:114948 )

• about 50% of peripheral T cell are activated at 5 months of age

• the fraction of activated/memory T cells in the spleen increases from nearly normal at 2 months of age to about 91% at 7 months of age

• these activated T cells express very high levels of FASL at 5 months of age

abnormal immune system organ morphology ( J:114948 )

enlarged spleen ( J:114948 )

• enlarged with disruption of the architecture, loss of white pulp, sclerosis , and hyalinization at 5 months of age

spleen hypoplasia ( J:114948 )

• gradual decline in total cells, T cells, and B cells

• T cells and B cells are about 160% of control at 2 months, 60% of control at 5 months and 23% (T cells) and 44% (B cells) of control at 7 months

• widespread apoptosis is seen at 16 weeks of age

lymph node hypoplasia ( J:114948 )

• gradual decline in B and T cell numbers in secondary lymphoid organs beginning after 2 months of age resulting in almost complete lymphopenia in the lymph nodes

• loss of B and T cells is at least in part the result of increased apoptosis

• at 5 months of age in 6 of 8 mice inguinal lymph nodes contain fewer than 0.1 million cells and at 7 months in 4 of 4 mice inguinal lymph nodes are almost empty

• treatment with a neutralizing Fasl antibody prevents loss of B and T cells from the inguinal lymph nodes

increased anti-single stranded DNA antibody level ( J:114948 )

• 3- to 8-fold increase in IgM and IgG antibodies for single stranded DNA; however, this is 2- to 3-fold lower than in mice homozygous for Fas^tm1.1Cgn and mice do not display the increase in double negative T cells or lymphoproliferative disease seen in Fas^lpr homozygotes

increased inflammatory response ( J:114948 )

liver inflammation ( J:114948 )

• mild to moderate inflammatory cell infiltration

kidney inflammation ( J:114948 )

• mild to moderate inflammatory cell infiltration

lung inflammation ( J:114948 )

• lung disease begins with infiltration of T and B cells predominantly around the arteries and bronchi around 5 months of age and this is accompanied by high levels of apoptosis

• treatment with a neutralizing Fasl antibody prevents lymphocyte infiltration

alveolitis ( J:114948 )

• intense alveolitis with infiltration of lymphocytes, neutrophils, and activated macrophages at 10 months of age

growth/size/body

weight loss ( J:114948 )

• at 10 months of age, mice develop a severe wasting syndrome with loss of about 30% of their body weight

enlarged spleen ( J:114948 )

• enlarged with disruption of the architecture, loss of white pulp, sclerosis , and hyalinization at 5 months of age

respiratory system

lung inflammation ( J:114948 )

• lung disease begins with infiltration of T and B cells predominantly around the arteries and bronchi around 5 months of age and this is accompanied by high levels of apoptosis

• treatment with a neutralizing Fasl antibody prevents lymphocyte infiltration

alveolitis ( J:114948 )

• intense alveolitis with infiltration of lymphocytes, neutrophils, and activated macrophages at 10 months of age

pulmonary fibrosis ( J:114948 )

• at 10 months of age, mice develop severe inflammatory pulmonary fibrosis with massive accumulation of elastic fibers and intense alveolitis

liver/biliary system

liver inflammation ( J:114948 )

• mild to moderate inflammatory cell infiltration

renal/urinary system

kidney inflammation ( J:114948 )

• mild to moderate inflammatory cell infiltration

hematopoietic system

increased T cell apoptosis ( J:114948 )

• loss of B and T cells is at least in part the result of increased apoptosis

abnormal thymus involution ( J:114948 )

• thymus cell numbers decline from normal at 2 months of age to about 50% and 10% of control at 5 and 7 months of age, respectively

• occasionally complete thymic involution is seen at 7 months of age

enlarged spleen ( J:114948 )

• enlarged with disruption of the architecture, loss of white pulp, sclerosis , and hyalinization at 5 months of age

increased double-negative T cell number ( J:114948 )

• treatment with a neutralizing Fasl antibody results in accumulation of Thy1+ B220+ CD4- CD8- cells similar to the phenotype of Fas^lpr homozygous mice

decreased B cell number ( J:114948 )

• gradual decline in B cell numbers in secondary lymphoid organs beginning after 2 months of age resulting in almost complete lymphopenia in the lymph nodes

• treatment with a neutralizing Fasl antibody prevents loss of B cells from the inguinal lymph nodes

increased memory T cell number ( J:114948 )

• the fraction of activated/memory T cells in the spleen increases from nearly normal at 2 months of age to about 91% at 7 months of age

decreased T cell number ( J:114948 )

• gradual decline in T cell numbers in secondary lymphoid organs beginning after 2 months of age resulting in almost complete lymphopenia in the lymph nodes

• treatment with a neutralizing Fasl antibody prevents loss of T cells from the inguinal lymph nodes

increased activated T cell number ( J:114948 )

• about 50% of peripheral T cell are activated at 5 months of age

• the fraction of activated/memory T cells in the spleen increases from nearly normal at 2 months of age to about 91% at 7 months of age

• these activated T cells express very high levels of FASL at 5 months of age

spleen hypoplasia ( J:114948 )

• gradual decline in total cells, T cells, and B cells

• T cells and B cells are about 160% of control at 2 months, 60% of control at 5 months and 23% (T cells) and 44% (B cells) of control at 7 months

• widespread apoptosis is seen at 16 weeks of age

cellular

increased T cell apoptosis ( J:114948 )

• loss of B and T cells is at least in part the result of increased apoptosis

endocrine/exocrine glands

abnormal thymus involution ( J:114948 )

• thymus cell numbers decline from normal at 2 months of age to about 50% and 10% of control at 5 and 7 months of age, respectively

• occasionally complete thymic involution is seen at 7 months of age

Genotype
MGI:3690547

cn5

• Allelic Composition: Fas^tm1Cgn/Fas^tm1Cgn; Tg(Lck-cre)I57Jxm/0
• Genetic Background: B6.Cg-Fas^tm1Cgn Tg(Lck-cre)I57Jxm

immune system

lymph node hypoplasia ( J:114948 )

• at 7 months of age, lymph nodes contain fewer than 0.1 million cells

Genotype
MGI:3690550

cn6

• Allelic Composition: Fas^tm1Cgn/Fas^tm1Cgn; Tg(Mx1-cre)1Cgn/0
• Genetic Background: B6.Cg-Fas^tm1Cgn Tg(Mx1-cre)1Cgn

immune system

abnormal immune system morphology ( J:114948 )

• after Poly(I) Poly(C) induction of cre expression mice develop the lymphoproliferative disease seen in Fas^tm1.1Cgn homozygtes

enlarged spleen ( J:114948 )

enlarged lymph nodes ( J:114948 )

hematopoietic system

enlarged spleen ( J:114948 )

growth/size/body

enlarged spleen ( J:114948 )

Genotype
MGI:3690553

cn7

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Fas^lpr/Fas^tm1Cgn; Tg(Cd4-cre)1Cwi/0
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * DBA/2 * MRL

immune system

enlarged spleen ( J:114948 )

• similar to mice with recombination only in T cells

increased double-negative T cell number ( J:114948 )

• similar to mice with recombination only in T cells

enlarged lymph nodes ( J:114948 )

• similar to mice with recombination only in T cells

hematopoietic system

enlarged spleen ( J:114948 )

• similar to mice with recombination only in T cells

increased double-negative T cell number ( J:114948 )

• similar to mice with recombination only in T cells

growth/size/body

enlarged spleen ( J:114948 )

• similar to mice with recombination only in T cells

Genotype
MGI:3690552

cn8

• Allelic Composition: Cd19^tm1(cre)Cgn/Cd19⁺; Fas^lpr/Fas^tm1Cgn
• Genetic Background: involves: 129P2/OlaHsd * C57BL/6 * MRL

immune system

enlarged spleen ( J:114948 )

• 5-fold enlargement

enlarged lymph nodes ( J:114948 )

• 17-fold enlargement in the lymph nodes

• weight of the enlarged lymph nodes is still 200- to 300-fold less than in Fas^tm1.1Cgn Fas^lpr trans-heterozygous mice

hematopoietic system

enlarged spleen ( J:114948 )

• 5-fold enlargement

growth/size/body

enlarged spleen ( J:114948 )

• 5-fold enlargement

Genotype
MGI:3690542

cn9

• Allelic Composition: Fas^tm1Cgn/Fas^tm1Cgn; Mog^tm1(cre)Gkl/Mog⁺; Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak
• Genetic Background: involves: 129S2/SvPas * C57BL/6

immune system

immune system phenotype ( J:114741 )

N • B and T cell distribution in the lymph nodes is normal

N • the fraction of B220+ T cells in the lymph nodes and the thymic distribution of CD4/CD8 cells are similar to wild-type

decreased susceptibility to experimental autoimmune encephalomyelitis ( J:114741 )

• mice are almost completely resistant to induction of experimental autoimmune encephalomyelitis (EAE) by injection of MOG p35-55

• almost no oligodendrocyte apoptosis after EAE induction unlike in wild-type mice

• reduction in demyelination and inflammation after induction of EAE is greater than in mutant mice wild-type for Tnfrsf1a

• 24 days after induction of EAE, minimal axonal injury is seen in spinal cords

Genotype
MGI:3690541

cn10

• Allelic Composition: Fas^tm1Cgn/Fas^tm1Cgn; Mog^tm1(cre)Gkl/Mog⁺
• Genetic Background: involves: C57BL/6

immune system

immune system phenotype ( J:114741 )

N • the fraction of B220+ T cells in the lymph nodes and the thymic distribution of CD4/CD8 cells are similar to wild-type

decreased susceptibility to experimental autoimmune encephalomyelitis ( J:114741 )

• reduction in the onset and severity, but not incidence, of experimental autoimmune encephalomyelitis (EAE) induced by injection of MOG p35-55

• demyelination induced by injection of MOG p35-55 is reduced by about 70% compared to wild-type

• perivascular and parenchymal infiltration by T lymphocytes and macrophages is also reduced after induction of EAE

• mild reduction in oligodendrocyte apoptosis after EAE induction

Genotype
MGI:3690551

cn11

• Allelic Composition: Fas^lpr/Fas^tm1Cgn; Tg(Cd4-cre)1Cwi/0
• Genetic Background: involves: C57BL/6 * DBA/2 * MRL

immune system

enlarged spleen ( J:114948 )

• 4 of 5 mice had 2 fold enlargement

increased double-negative T cell number ( J:114948 )

enlarged lymph nodes ( J:114948 )

• 12-fold enlargement in the lymph nodes

• weight of the enlarged lymph nodes is still 200- to 300-fold less than in Fas^tm1.1Cgn Fas^lpr trans-heterozygous mice

hematopoietic system

enlarged spleen ( J:114948 )

• 4 of 5 mice had 2 fold enlargement

increased double-negative T cell number ( J:114948 )

growth/size/body

enlarged spleen ( J:114948 )

• 4 of 5 mice had 2 fold enlargement

Genotype
MGI:3690543

cx12

• Allelic Composition: Fas^tm1Cgn/Fas^tm1Cgn; Tnfrsf1a^tm1Mak/Tnfrsf1a^tm1Mak
• Genetic Background: involves: 129S2/SvPas * C57BL/6

immune system

decreased susceptibility to experimental autoimmune encephalomyelitis ( J:114741 )

• reduction in the onset and severity, but not incidence of experimental autoimmune encephalomyelitis (EAE) induced by injection of MOG p35-55

• about a 75% reduction in oligodendrocyte apoptosis after EAE induction compared to wild-type mice

• inflammation after EAE induction is also reduced